Objective: Dabigatran is a new non-vitamin K antagonist (VKA) anticoagulant with anti-thrombin action, with supposedly fewer haemorrhagic complications. However, there are actually no established agents to reverse its effect, nor specific coagulation time tests for monitoring it.
Materials And Methods: An observational prospective study was developed, noting epidemiological, clinical and therapeutic features among subjects with epistaxis treated with dabigatran. Results were compared with a group of epistaxis cases of individuals under anticoagulant therapy with VKA (acenocoumarol) and a control group without anticoagulation.
Results: Since its inclusion in our health system almost 3 years ago, 19 patients with epistaxis and concomitant use of dabigatran have been attended at the Emergency Unit in our hospital, as against 59 under VKA therapy and 144 without anticoagulation, with a mean admittance rate of 26%, 28% and 14%, respectively. In 3 out of 5 individuals admitted due to dabigatran treatment, previously unobserved renal failure was detected. Blood transfusion was needed in 80% of patients using dabigatran, 58% using VKA and 23% without anticoagulation. Invasive procedures to control nosebleed were required in 80%, 35% and 21%, respectively. Although haemorrhagic risk was lower in dabigatran cases, they showed the longest stay in the hospital when compared to the other groups.
Conclusions: With dabigatran, there are fewer cases of severe epistaxis than with acenocoumarol, but controlling them is more difficult.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.otorri.2014.02.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Appropriateness of direct oral anticoagulant dosing in patients with atrial fibrillation at a tertiary care hospital in Thailand.
Explor Res Clin Soc Pharm
December 2024
Department of Pharmacy Practice, College of Pharmacy, Rangsit University, Pathum Thani, Thailand.
Article Synopsis
- A study was conducted in Thailand to evaluate the appropriateness of direct oral anticoagulant (DOAC) dosing in hospitalized patients with atrial fibrillation (AF), revealing that many patients were not dosed according to guidelines.
- The study analyzed 120 patients, finding that the overall prevalence of appropriate DOAC dosing was 63.3%, but about one-third received inappropriate doses, with 20% overdosed and 16.7% underdosed.
- Dabigatran had the highest overdosing rate (90%), while apixaban exhibited the most underdosing (21.9%), emphasizing a significant gap in proper anticoagulant management.
Long-term cognitive function changes with non-vitamin K oral anticoagulants in older patients with atrial fibrillation. A multicenter cohort study.
Eur J Clin Invest
January 2025
Department of Medical and Surgical Sciences, University Magna Græcia of Catanzaro, Catanzaro, Italy.
Article Synopsis
- Atrial fibrillation (AF) in older patients is linked to cognitive decline and dementia, with ongoing debate about the benefits of anticoagulants on cognitive function.
- This study involved 983 older patients comparing the cognitive decline between those on non-vitamin K oral anticoagulants (NOACs) and vitamin K antagonists (VKAs) using the Mini Mental State Examination (MMSE) score over an average of 7.2 years.
- Results showed that patients on NOACs had a significantly lesser decline in cognitive function compared to VKAs, indicating that NOACs may be more beneficial for preserving cognitive health in older AF patients despite their higher age and comorbidities.
Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling.
Int J Mol Sci
August 2024
Yajnavalkaa Banerrji Research Group, College of Medicine and Health Sciences, Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Health, Dubai P.O. Box 505055, United Arab Emirates.
Non-vitamin K oral anticoagulants (NOACs) have revolutionized anticoagulant therapy, offering improved safety and efficacy over traditional agents like warfarin. This review comprehensively examines the dual roles of NOACs-apixaban, rivaroxaban, edoxaban, and dabigatran-not only as anticoagulants, but also as modulators of inflammation via protease-activated receptor (PAR) signaling. We highlight the unique pharmacotherapeutic properties of each NOAC, supported by key clinical trials demonstrating their effectiveness in preventing thromboembolic events.
View Article and Find Full Text PDFEffectiveness and safety of non-vitamin K antagonist oral anticoagulants in low-weight patients with atrial fibrillation.
J Thromb Thrombolysis
October 2024
Department of Pharmacy, School of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei City, Taiwan.
It remains unclear whether non-vitamin K antagonist oral anticoagulants (NOACs) are more effective and safer than warfarin in low-weight patients with atrial fibrillation (AF). Here, we retrospectively compared the effectiveness and safety of NOACs with those of warfarin in low-weight patients with AF. We extracted the July 2011-September 2022 data of patients with AF treated with a NOAC (dabigatran, rivaroxaban, apixaban, or edoxaban) or warfarin at a tertiary hospital.
View Article and Find Full Text PDFAntithrombotic prophylaxis following total knee arthroplasty: a level I Bayesian network meta-analysis.
Eur J Orthop Surg Traumatol
August 2024
Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH University Medical Centre, 52074, Aachen, Germany.
Introduction: Venous thromboembolism (VTE) is a major concern following total knee arthroplasty (TKA). The optimal pharmacological prophylaxis remains, however, controversial. The present investigation compared several non-vitamin K antagonist oral anticoagulants commonly employed as VTE prophylaxis following TKA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!